Interconnection between DNA damage, senescence, inflammation, and cancer

Frontiers in Bioscience - Landmark

Volumn 22, Issue 2, 2017, Pages 348-369

  Wunderlich, Roland ^a   Ruehle, Paul Friedrich ^b   Deloch, Lisa ^b   Unger, Kristian ^a   Hess, Julia ^a   Zitzelsberger, Horst ^a   Lauber, Kirsten ^c   Frey, Benjamin ^b   Gaipl, Udo S ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; DNA damage; Inflammation; Radiation; Review; SASP; Senescence

Indexed keywords

ANIMAL; APOPTOSIS; CELL AGING; CELL DEATH; DNA DAMAGE; DNA REPAIR; HUMAN; INFLAMMATION; NEOPLASM;

ANIMALS; APOPTOSIS; CELL DEATH; CELLULAR SENESCENCE; DNA DAMAGE; DNA REPAIR; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 85031091800     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4488     Document Type: Review

References (182)

1. J. H. Hoeijmakers: DNA damage, aging, and cancer. N Engl J Med, 361(15), 1475-85 (2009) DOI: 10.1056/NEJMra0804615
2. S. D. McCulloch and T. A. Kunkel: The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res, 18(1), 148-61 (2008) DOI: 10.1038/cr.2008.4
3. A. Ciccia and S. J. Elledge: The DNA damage response: making it safe to play with knives. Mol Cell, 40(2), 179-204 (2010) DOI: 10.1016/j.molcel.2010.09.019
4. J. L. Ravanat, T. Douki and J. Cadet: Direct and indirect effects of UV radiation on DNA and its components. J Photochem Photobiol B, 63(1-3), 88-102 (2001) DOI: 10.1016/S1011-1344(01)00206-8
5. J. F. Ward: DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol, 35, 95-125 (1988) DOI: 10.1016/S0079-6603(08)60611-X
6. M. A. Kang, E. Y. So, A. L. Simons, D. R. Spitz and T. Ouchi: DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway. Cell Death Dis, 3, e249 (2012) DOI: 10.1038/cddis.2011.134
7. M. F. Lavin: ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene, 26(56), 7749-58 (2007) DOI: 10.1038/sj.onc.1210880
8. J. Falck, J. Coates and S. P. Jackson: Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature, 434(7033), 605-11 (2005) DOI: 10.1038/nature03442
9. J. H. Lee and T. T. Paull: ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science, 308(5721), 551-4 (2005) DOI: 10.1126/science.1108297
10. T. Uziel, Y. Lerenthal, L. Moyal, Y. Andegeko, L. Mittelman and Y. Shiloh: Requirement of the MRN complex for ATM activation by DNA damage. EMBO J, 22(20), 5612-21 (2003) DOI: 10.1093/emboj/cdg541
11. D. Cortez, S. Guntuku, J. Qin and S. J. Elledge: ATR and ATRIP: partners in checkpoint signaling. Science, 294(5547), 1713-6 (2001) DOI: 10.1126/science.1065521
12. L. Zou and S. J. Elledge: Sensing DNA damage through ATRIP recognition of RPAssDNA complexes. Science, 300(5625), 1542-8 (2003) DOI: 10.1126/science.1083430
13. J. C. Harrison and J. E. Haber: Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet, 40, 209-35 (2006) DOI: 10.1.146/annurev.genet.40.0.51206.1.05231 DOI: 10.1146/annurev.genet.40.051206.105231
14. J. W. Harper and S. J. Elledge: The DNA damage response: ten years after. Mol Cell, 28(5), 739-45 (2007) DOI: 10.1016/j.molcel.2007.11.015
15. J. Bartek and J. Lukas: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3(5), 421-9 (2003) DOI: 10.1016/S1535-6108(03)00110-7
16. D. Cortez, Y. Wang, J. Qin and S. J. Elledge: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science, 286(5442), 1162-6 (1999) DOI: 10.1126/science.286.5442.1162
17. S. T. Kim, B. Xu and M. B. Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev, 16(5), 560-70 (2002) DOI: 10.1101/gad.970602
18. J. Lukas, C. Lukas and J. Bartek: Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst), 3(8-9), 997-1007 (2004) DOI: 10.1016/j.dnarep.2004.03.006
19. G. Iliakis, Y. Wang, J. Guan and H. Wang: DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene, 22(37), 5834-47 (2003) DOI: 10.1038/sj.onc.1206682
20. M. B. Kastan and J. Bartek: Cell-cycle checkpoints and cancer. Nature, 432(7015), 316-23 (2004) DOI: 10.1038/nature03097
21. B. B. Zhou and S. J. Elledge: The DNA damage response: putting checkpoints in perspective. Nature, 408(6811), 433-9 (2000) DOI: 10.1038/35044005
22. F. Altieri, C. Grillo, M. Maceroni and S. Chichiarelli: DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal, 10(5), 891-937 (2008) DOI: 10.1089/ars.2007.1830
23. K. K. Khanna and S. P. Jackson: DNA doublestrand breaks: signaling, repair and the cancer connection. Nat Genet, 27(3), 247-54 (2001) DOI: 10.1038/85798
24. D. C. van Gent, J. H. Hoeijmakers and R. Kanaar: Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet, 2(3), 196-206 (2001) DOI: 10.1038/35056049
25. A. J. Hartlerode and R. Scully: Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J, 423(2), 157-68 (2009) DOI: 10.1042/BJ20090942
26. B. Pardo, B. Gomez-Gonzalez and A. Aguilera: DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol Life Sci, 66(6), 1039-56 (2009) DOI: 10.1007/s00018-009-8740-3
27. X. Li and W. D. Heyer: Homologous recombination in DNA repair and DNA damage tolerance. Cell Res, 18(1), 99-113 (2008) DOI: 10.1038/cr.2008.1
28. Z. Mao, M. Bozzella, A. Seluanov and V. Gorbunova: DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle, 7(18), 2902-6 (2008) DOI: 10.4161/cc.7.18.6679
29. M. R. Lieber: The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem, 79, 181-211 (2010) DOI: 10.1146/annurev. biochem.052308.093131
30. O. Surova and B. Zhivotovsky: Various modes of cell death induced by DNA damage. Oncogene, 32(33), 3789-97 (2013) DOI: 10.1038/onc.2012.556
31. L. Hayflick: The Limited in vitro Lifetime of Human Diploid Cell Strains. Exp Cell Res, 37, 614-36 (1965) DOI: 10.1016/0014-4827(65)90211-9
32. L. Hayflick and P. S. Moorhead: The serial cultivation of human diploid cell strains. Exp Cell Res, 25, 585-621 (1961) DOI: 10.1016/0014-4827(61)90192-6
33. V. C. Gray-Schopfer, S. C. Cheong, H. Chong, J. Chow, T. Moss, Z. A. Abdel-Malek, R. Marais, D. Wynford-Thomas and D. C. Bennett: Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer, 95(4), 496-505 (2006) DOI: 10.1038/sj.bjc.6603283
34. R. Di Micco, M. Fumagalli, A. Cicalese, S. Piccinin, P. Gasparini, C. Luise, C. Schurra, M. Garre, P. G. Nuciforo, A. Bensimon, R. Maestro, P. G. Pelicci and F. d'Adda di Fagagna: Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444(7119), 638-42 (2006) DOI: 10.1038/nature05327
35. W. J. Mooi and D. S. Peeper: Oncogeneinduced cell senescence-halting on the road to cancer. N Engl J Med, 355(10), 1037-46 (2006) DOI: 10.1056/NEJMra062285
36. Z. Chen, L. C. Trotman, D. Shaffer, H. K. Lin, Z. A. Dotan, M. Niki, J. A. Koutcher, H. I. Scher, T. Ludwig, W. Gerald, C. Cordon-Cardo and P. P. Pandolfi: Crucial role of p53-dependent cellular senescence in suppression of Ptendeficient tumorigenesis. Nature, 436(7051), 725-30 (2005) DOI: 10.1038/nature03918
37. A. Shamma, Y. Takegami, T. Miki, S. Kitajima, M. Noda, T. Obara, T. Okamoto and C. Takahashi: Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell, 15(4), 255-69 (2009)1 No DOI Found
38. C. Gewinner, Z. C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, D. Bowtell, J. Barretina, W. M. Lin, L. Rameh, L. Salmena, P. P. Pandolfi and L. C. Cantley: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell, 16(2), 115-25 (2009) DOI: 10.1016/j.ccr.2009.06.006
39. J. G. Jackson and O. M. Pereira-Smith: p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res, 66(17), 8356-60 (2006) DOI: 10.1158/0008-5472.CAN-06-1752
40. J. M. Espinosa, R. E. Verdun and B. M. Emerson: p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell, 12(4), 1015-27 (2003) DOI: 10.1016/S1097-2765(03)00359-9
41. I. P. Trougakos, A. Saridaki, G. Panayotou and E. S. Gonos: Identification of differentially expressed proteins in senescent human embryonic fibroblasts. Mech Ageing Dev, 127(1), 88-92 (2006) DOI: 10.1016/j.mad.2005.08.009
42. E. B. Golden, I. Pellicciotta, S. Demaria, M. H. Barcellos-Hoff and S. C. Formenti: The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol, 2, 88 (2012) DOI: 10.3389/fonc.2012.00088
43. G. P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith and et al.: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A, 92(20), 9363-7 (1995) DOI: 10.1073/pnas.92.20.9363
44. U. Herbig, M. Ferreira, L. Condel, D. Carey and J. M. Sedivy: Cellular senescence in aging primates. Science, 311(5765), 1257 (2006) DOI: 10.1126/science.1122446
45. F. Rodier, D. P. Munoz, R. Teachenor, V. Chu, O. Le, D. Bhaumik, J. P. Coppe, E. Campeau, C. M. Beausejour, S. H. Kim, A. R. Davalos and J. Campisi: DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci, 124(Pt 1), 68-81 (2011) DOI: 10.1242/jcs.071340
46. G. Kroemer, L. Galluzzi, P. Vandenabeele, J. Abrams, E. S. Alnemri, E. H. Baehrecke, M. V. Blagosklonny, W. S. El-Deiry, P. Golstein, D. R. Green, M. Hengartner, R. A. Knight, S. Kumar, S. A. Lipton, W. Malorni, G. Nunez, M. E. Peter, J. Tschopp, J. Yuan, M. Piacentini, B. Zhivotovsky, G. Melino and D. Nomenclature Committee on Cell: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ, 16(1), 3-11 (2009) DOI: 10.1038/cdd.2008.150
47. A. Barascu, C. Le Chalony, G. Pennarun, D. Genet, N. Imam, B. Lopez and P. Bertrand: Oxidative stress induces an ATM-independent senescence pathway through p38 MAPKmediated lamin B1 accumulation. EMBO J, 31(5), 1080-94 (2012) DOI: 10.1038/emboj.2011.492
48. Q. M. Chen, K. R. Prowse, V. C. Tu, S. Purdom and M. H. Linskens: Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp Cell Res, 265(2), 294-303 (2001) DOI: 10.1006/excr.2001.5182
49. S. Parrinello, E. Samper, A. Krtolica, J. Goldstein, S. Melov and J. Campisi: Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol, 5(8), 741-7 (2003) DOI: 10.1038/ncb1024
50. D. X. Mason, T. J. Jackson and A. W. Lin: Molecular signature of oncogenic rasinduced senescence. Oncogene, 23(57), 9238-46 (2004) DOI: 10.1038/sj.onc.1208172
51. D. N. Shelton, E. Chang, P. S. Whittier, D. Choi and W. D. Funk: Microarray analysis of replicative senescence. Curr Biol, 9(17), 939-45 (1999) DOI: 10.1016/S0960-9822(99)80420-5
52. J. P. Coppe, P. Y. Desprez, A. Krtolica and J. Campisi: The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol, 5, 99-118 (2010) DOI: 10.1146/annurev-pathol-121808-102144
53. T. Kuilman, C. Michaloglou, L. C. Vredeveld, S. Douma, R. van Doorn, C. J. Desmet, L. A. Aarden, W. J. Mooi and D. S. Peeper: Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 133(6), 1019-31 (2008) DOI: 10.1016/j.cell.2008.03.039
54. J. C. Acosta, A. O'Loghlen, A. Banito, M. V. Guijarro, A. Augert, S. Raguz, M. Fumagalli, M. Da Costa, C. Brown, N. Popov, Y. Takatsu, J. Melamed, F. d'Adda di Fagagna, D. Bernard, E. Hernando and J. Gil: Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, 133(6), 1006-18 (2008) DOI: 10.1016/j.cell.2008.03.038
55. A. Freund, C. K. Patil and J. Campisi: p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J, 30(8), 1536-48 (2011) DOI: 10.1038/emboj.2011.69
56. A. V. Orjalo, D. Bhaumik, B. K. Gengler, G. K. Scott and J. Campisi: Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A, 106(40), 17031-6 (2009) DOI: 10.1073/pnas.0905299106
57. R. M. Laberge, Y. Sun, A. V. Orjalo, C. K. Patil, A. Freund, L. Zhou, S. C. Curran, A. R. Davalos, K. A. Wilson-Edell, S. Liu, C. Limbad, M. Demaria, P. Li, G. B. Hubbard, Y. Ikeno, M. Javors, P. Y. Desprez, C. C. Benz, P. Kapahi, P. S. Nelson and J. Campisi: MTOR regulates the pro-tumorigenic senescenceassociated secretory phenotype by promoting IL1A translation. Nat Cell Biol, 17(8), 1049-61 (2015) DOI: 10.1038/ncb3195
58. N. Herranz, S. Gallage, M. Mellone, T. Wuestefeld, S. Klotz, C. J. Hanley, S. Raguz, J. C. Acosta, A. J. Innes, A. Banito, A. Georgilis, A. Montoya, K. Wolter, G. Dharmalingam, P. Faull, T. Carroll, J. P. Martinez-Barbera, P. Cutillas, F. Reisinger, M. Heikenwalder, R. A. Miller, D. Withers, L. Zender, G. J. Thomas and J. Gil: mTOR regulates MAPKAPK2 translation to control the senescenceassociated secretory phenotype. Nat Cell Biol, 17(9), 1205-17 (2015) DOI: 10.1038/ncb3225
59. H. L. Pahl: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18(49), 6853-66 (1999) DOI: 10.1038/sj.onc.1203239
60. A. Lasry and Y. Ben-Neriah: Senescenceassociated inflammatory responses: aging and cancer perspectives. Trends Immunol, 36(4), 217-28 (2015) DOI: 10.1016/j.it.2015.02.009
61. C. Nathan: Points of control in inflammation. Nature, 420(6917), 846-52 (2002) DOI: 10.1038/nature01320
62. M. Philip, D. A. Rowley and H. Schreiber: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol, 14(6), 433-9 (2004) DOI: 10.1016/j.semcancer.2004.06.006
63. M. Karin and F. R. Greten: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5(10), 749-59 (2005) DOI: 10.1038/nri1703
64. M. Karin, T. Lawrence and V. Nizet: Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell, 124(4), 823-35 (2006) DOI: 10.1016/j.cell.2006.02.016
65. R. Medzhitov: Origin and physiological roles of inflammation. Nature, 454(7203), 428-435 (2008) DOI: 10.1038/nature07201
66. M. Keller, A. Rüegg, S. Werner and H.-D. Beer: Active Caspase-1 Is a Regulator of Unconventional Protein Secretion. Cell, 132(5), 818-831 (2008) DOI: 10.1016/j.cell.2007.12.040
67. O. Takeuchi and S. Akira: Pattern recognition receptors and inflammation. Cell, 140(6), 805-20 (2010) DOI: 10.1016/j.cell.2010.01.022
68. J. S. Arthur and S. C. Ley: Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol, 13(9), 679-92 (2013) DOI: 10.1038/nri3495
69. S. L. Foster, D. C. Hargreaves and R. Medzhitov: Gene-specific control of inflammation by TLRinduced chromatin modifications. Nature, 447(7147), 972-8 (2007) DOI: 10.1038/nature05836
70. V. R. Ramirez-Carrozzi, A. A. Nazarian, C. C. Li, S. L. Gore, R. Sridharan, A. N. Imbalzano and S. T. Smale: Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev, 20(3), 282-96 (2006) DOI: 10.1101/gad.1383206
71. G. Bonizzi and M. Karin: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 25(6), 280-8 (2004) DOI: 10.1016/j.it.2004.03.008
72. S. Ghosh and M. S. Hayden: Celebrating 25 years of NF-kappaB research. Immunol Rev, 246(1), 5-13 (2012) DOI: 10.1111/j.1600-065X.2012.01111.x
73. M. Pasparakis: Role of NF-kappaB in epithelial biology. Immunol Rev, 246(1), 346-58 (2012) DOI: 10.1111/j.1600-065X.2012.01109.x
74. M. Karin: Nuclear factor-kappaB in cancer development and progression. Nature, 441(7092), 431-6 (2006) DOI: 10.1038/nature04870
75. A. Iwasaki and R. Medzhitov: Control of adaptive immunity by the innate immune system. Nat Immunol, 16(4), 343-53 (2015) DOI: 10.1038/ni.3123
76. A. T. Lau, Y. Wang and J. F. Chiu: Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem, 104(2), 657-67 (2008) DOI: 10.1002/jcb.21655
77. M. Merad, P. Sathe, J. Helft, J. Miller and A. Mortha: The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol, 31, 563-604 (2013) DOI: 10.1146/annurev-immunol -020711-074950
78. S. E. Headland and L. V. Norling: The resolution of inflammation: Principles and challenges. Seminars in Immunology(0) (2015) No DOI Found
79. T. S. Gastardelo, A. S. Damazo, J. Dalli, R. J. Flower, M. Perretti and S. M. Oliani: Functional and Ultrastructural Analysis of Annexin A1 and Its Receptor in Extravasating Neutrophils during Acute Inflammation. The American Journal of Pathology, 174(1), 177-183 (2009) DOI: 10.2353/ajpath.2009.080342
80. D. El Kebir, L. Jozsef, T. Khreiss, W. Pan, N. A. Petasis, C. N. Serhan and J. G. Filep: Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol, 179(1), 616-22 (2007) DOI: 10.4049/jimmunol.179.1.616
81. P. Maderna, D. C. Cottell, T. Toivonen, N. Dufton, J. Dalli, M. Perretti and C. Godson: FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J, 24(11), 4240-9 (2010) DOI: 10.1096/fj.10-159913
82. M. Scannell, M. B. Flanagan, A. deStefani, K. J. Wynne, G. Cagney, C. Godson and P. Maderna: Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol, 178(7), 4595-605 (2007) DOI: 10.4049/jimmunol.178.7.4595
83. K. E. Blume, S. Soeroes, M. Waibel, H. Keppeler, S. Wesselborg, M. Herrmann, K. Schulze-Osthoff and K. Lauber: Cell surface externalization of annexin A1 as a failsafe mechanism preventing inflammatory responses during secondary necrosis. J Immunol, 183(12), 8138-47 (2009) DOI: 10.4049/jimmunol.0902250
84. J. Bystrom, I. Evans, J. Newson, M. Stables, I. Toor, N. van Rooijen, M. Crawford, P. Colville-Nash, S. Farrow and D. W. Gilroy: Resolutionphase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood, 112(10), 4117-27 (2008) DOI: 10.1182/blood-2007-12-129767
85. S. Gordon: Alternative activation of macrophages. Nat Rev Immunol, 3(1), 23-35 (2003) DOI: 10.1038/nri978
86. S. Schif-Zuck, N. Gross, S. Assi, R. Rostoker, C. N. Serhan and A. Ariel: Saturated-efferocytosis generates pro-resolving CD11blow macrophages: Modulation by resolvins and glucocorticoids. European Journal of Immunology, 41(2), 366-379 (2011) DOI: 10.1002/eji.201040801
87. M.-L. N. Huynh, V. A. Fadok and P. M. Henson: Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. The Journal of Clinical Investigation, 109(1), 41-50 (2002) DOI: 10.1172/JCI0211638
88. C. N. Serhan and J. Savill: Resolution of inflammation: the beginning programs the end. Nat Immunol, 6(12), 1191-7 (2005) DOI: 10.1038/ni1276
89. R. Rajakariar, T. Lawrence, J. Bystrom, M. Hilliard, P. Colville-Nash, G. Bellingan, D. Fitzgerald, M. M. Yaqoob and D. W. Gilroy: Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood, 111(8), 4184-92 (2008) DOI: 10.1182/blood-2007-08-108936
90. A. Ariel, N. Chiang, M. Arita, N. A. Petasis and C. N. Serhan: Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signalregulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol, 170(12), 6266-72 (2003) DOI: 10.4049/jimmunol.170.12.6266
91. T. Lawrence, M. Bebien, G. Y. Liu, V. Nizet and M. Karin: IKK(alpha) limits macrophage NF-(kappa)B activation and contributes to the resolution of inflammation. Nature, 434(7037), 1138-1143 (2005) DOI: 10.1038/nature03491
92. D. L. Boone, E. E. Turer, E. G. Lee, R.-C. Ahmad, M. T. Wheeler, C. Tsui, P. Hurley, M. Chien, S. Chai, O. Hitotsumatsu, E. McNally, C. Pickart and A. Ma: The ubiquitin-modifying enzyme A20 is required for termination of Tolllike receptor responses. Nat Immunol, 5(10), 1052-1060 (2004) DOI: 10.1038/ni1110
93. W. S. Alexander and D. J. Hilton: The Role of Suppressors of Cytokine Signaling (SOCS) Proteins in Regulation of the Immune Response. Annual Review of Immunology, 22(1), 503-529 (2004) DOI: 10.1146/annurev. immunol.22.091003.090312
94. W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo and S. W. Lowe: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445(7128), 656-60 (2007) DOI: 10.1038/nature05529
95. T. W. Kang, T. Yevsa, N. Woller, L. Hoenicke, T. Wuestefeld, D. Dauch, A. Hohmeyer, M. Gereke, R. Rudalska, A. Potapova, M. Iken, M. Vucur, S. Weiss, M. Heikenwalder, S. Khan, J. Gil, D. Bruder, M. Manns, P. Schirmacher, F. Tacke, M. Ott, T. Luedde, T. Longerich, S. Kubicka and L. Zender: Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 479(7374), 547-51 (2011) DOI: 10.1038/nature10599
96. Y. Chien, C. Scuoppo, X. Wang, X. Fang, B. Balgley, J. E. Bolden, P. Premsrirut, W. Luo, A. Chicas, C. S. Lee, S. C. Kogan and S. W. Lowe: Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev, 25(20), 2125-36 (2011) DOI: 10.1101/gad.17276711
97. A. Bitto, C. Sell, E. Crowe, A. Lorenzini, M. Malaguti, S. Hrelia and C. Torres: Stress-induced senescence in human and rodent astrocytes. Exp Cell Res, 316(17), 2961-8 (2010) DOI: 10.1016/j.yexcr.2010.06.021
98. A. Salminen, J. Ojala, K. Kaarniranta, A. Haapasalo, M. Hiltunen and H. Soininen: Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci, 34(1), 3-11 (2011) DOI: 10.1111/j.1460-9568.2011.07738.x
99. S. Roberts, E. H. Evans, D. Kletsas, D. C. Jaffray and S. M. Eisenstein: Senescence in human intervertebral discs. Eur Spine J, 15 Suppl 3, S312-6 (2006) DOI: 10.1007/s00586-006-0126-8
100. A. Shane Anderson and R. F. Loeser: Why is osteoarthritis an age-related disease? Best Pract Res Clin Rheumatol, 24(1), 15-26 (2010) DOI: 10.1016/j.berh.2009.08.006
101. B. Bhatia, A. S. Multani, L. Patrawala, X. Chen, T. Calhoun-Davis, J. Zhou, L. Schroeder, R. Schneider-Broussard, J. Shen, S. Pathak, S. Chang and D. G. Tang: Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int J Cancer, 122(7), 1483-95 (2008) DOI: 10.1002/ijc.23222
102. A. Krtolica, S. Parrinello, S. Lockett, P. Y. Desprez and J. Campisi: Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A, 98(21), 12072-7 (2001) DOI: 10.1073/pnas.211053698
103. D. Liu and P. J. Hornsby: Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res, 67(7), 3117-26 (2007) DOI: 10.1158/0008-5472.CAN-06-3452
104. M. Rielland, D. J. Cantor, R. Graveline, C. Hajdu, L. Mara, D. Diaz Bde, G. Miller and G. David: Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J Clin Invest, 124(5), 2125-35 (2014) DOI: 10.1172/JCI72619
105. J. S. Price, J. G. Waters, C. Darrah, C. Pennington, D. R. Edwards, S. T. Donell and I. M. Clark: The role of chondrocyte senescence in osteoarthritis. Aging Cell, 1(1), 57-65 (2002) DOI: 10.1046/j.1474-9728.2002.00008.x
106. E. Vasile, Y. Tomita, L. F. Brown, O. Kocher and H. F. Dvorak: Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J, 15(2), 458-66 (2001) DOI: 10.1096/fj.00-0051com
107. C. Matthews, I. Gorenne, S. Scott, N. Figg, P. Kirkpatrick, A. Ritchie, M. Goddard and M. Bennett: Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res, 99(2), 156-64 (2006) DOI: 10.1161/01.RES.0000233315.38086.bc
108. J. C. Jeyapalan, M. Ferreira, J. M. Sedivy and U. Herbig: Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev, 128(1), 36-44 (2007) DOI: 10.1016/j.mad.2006.11.008
109. P. J. Linton and K. Dorshkind: Age-related changes in lymphocyte development and function. Nat Immunol, 5(2), 133-9 (2004) DOI: 10.1038/ni1033
110. A. C. Shaw, S. Joshi, H. Greenwood, A. Panda and J. M. Lord: Aging of the innate immune system. Curr Opin Immunol, 22(4), 507-13 (2010) DOI: 10.1016/j.coi.2010.05.003
111. J. Campisi: Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell, 120(4), 513-22 (2005) DOI: 10.1016/j.cell.2005.02.003
112. C. Bavik, I. Coleman, J. P. Dean, B. Knudsen, S. Plymate and P. S. Nelson: The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res, 66(2), 794-802 (2006) DOI: 10.1158/0008-5472.CAN-05-1716
113. J. P. Coppe, K. Kauser, J. Campisi and C. M. Beausejour: Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem, 281(40), 29568-74 (2006) DOI: 10.1074/jbc.M603307200
114. T. K. Dilley, G. T. Bowden and Q. M. Chen: Novel mechanisms of sublethal oxidant toxicity: induction of premature senescence in human fibroblasts confers tumor promoter activity. Exp Cell Res, 290(1), 38-48 (2003) DOI: 10.1016/S0014-4827(03)00308-2
115. D. Yang, S. G. Elner, Z. M. Bian, G. O. Till, H. R. Petty and V. M. Elner: Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res, 85(4), 462-72 (2007) DOI: 10.1016/j.exer.2007.06.013
116. I. L. Aivaliotis, I. S. Pateras, M. Papaioannou, C. Glytsou, K. Kontzoglou, E. O. Johnson and V. Zoumpourlis: How do cytokines trigger genomic instability? J Biomed Biotechnol, 2012, 536761 (2012) DOI: 10.1155/2012/536761
117. J. Campisi, J. K. Andersen, P. Kapahi and S. Melov: Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol, 21(6), 354-9 (2011) DOI: 10.1016/j.semcancer.2011.09.001
118. S. Vasto, G. Candore, C. R. Balistreri, M. Caruso, G. Colonna-Romano, M. P. Grimaldi, F. Listi, D. Nuzzo, D. Lio and C. Caruso: Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev, 128(1), 83-91 (2007) DOI: 10.1016/j.mad.2006.11.015
119. L. Ferrucci, A. Ble, S. Bandinelli, F. Lauretani, K. Suthers and J. M. Guralnik: A flame burning within. Aging Clin Exp Res, 16(3), 240-3 (2004) DOI: 10.1007/BF03327390
120. G. Nelson, J. Wordsworth, C. Wang, D. Jurk, C. Lawless, C. Martin-Ruiz and T. von Zglinicki: A senescent cell bystander effect: senescence-induced senescence. Aging Cell, 11(2), 345-9 (2012) DOI: 10.1111/j.1474-9726.2012.00795.x
121. D. Hanahan and R. A. Weinberg: Hallmarks of cancer: the next generation. Cell, 144(5), 646-74 (2011) DOI: 10.1016/j.cell.2011.02.013
122. O. Brostrom, R. Lofberg, B. Nordenvall, A. Ost and G. Hellers: The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol, 22(10), 1193-9 (1987) DOI: 10.3109/00365528708996463
123. S. R. Hamilton: Colorectal carcinoma in patients with Crohn's disease. Gastroenterology, 89(2), 398-407 (1985) No DOI Found
124. T. Hagemann, F. Balkwill and T. Lawrence: Inflammation and cancer: a double-edged sword. Cancer Cell, 12(4), 300-1 (2007) DOI: 10.1016/j.ccr.2007.10.005
125. N. Figueiredo, A. Chora, H. Raquel, N. Pejanovic, P. Pereira, B. Hartleben, A. Neves-Costa, C. Moita, D. Pedroso, A. Pinto, S. Marques, H. Faridi, P. Costa, R. Gozzelino, J. L. Zhao, M. P. Soares, M. Gama-Carvalho, J. Martinez, Q. Zhang, G. Doring, M. Grompe, J. P. Simas, T. B. Huber, D. Baltimore, V. Gupta, D. R. Green, J. A. Ferreira and L. F. Moita: Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity, 39(5), 874-84 (2013) DOI: 10.1016/j.immuni.2013.08.039
126. B. Frischholz, R. Wunderlich, P. F. Ruhle, C. Schorn, F. Rodel, L. Keilholz, R. Fietkau, U. S. Gaipl and B. Frey: Reduced secretion of the inflammatory cytokine IL-1beta by stimulated peritoneal macrophages of radiosensitive Balb/c mice after exposure to 0.5. or 0.7. Gy of ionizing radiation. Autoimmunity (2013) DOI: 10.3109/08916934.2012.747522
127. O. J. Ott, M. Niewald, H. D. Weitmann, I. Jacob, I. A. Adamietz, U. Schaefer, L. Keilholz, R. Heyd, R. Muecke and D. German Cooperative Group on Radiotherapy for Benign: DEGRO guidelines for the radiotherapy of non-malignant disorders: Part II: Painful degenerative skeletal disorders. Strahlenther Onkol (2014) No DOI Found
128. M. H. Seegenschmiedt, A. Katalinic, H. B. Makoski, W. Haase, G. Gademann and E. Hassenstein: (Radiotherapy of benign diseases: a pattern of care study in Germany). Strahlenther Onkol, 175(11), 541-7 (1999) DOI: 10.1007/s000660050038
129. M. H. Seegenschmiedt, O. Micke and N. Willich: Radiation therapy for nonmalignant diseases in Germany. Current concepts and future perspectives. Strahlenther Onkol, 180(11), 718-30 (2004) DOI: 10.1007/s00066-004-9197-9
130. O. J. Ott, S. Hertel, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: Benign painful shoulder syndrome: initial results of a singlecenter prospective randomized radiotherapy dose-optimization trial. Strahlenther Onkol, 188(12), 1108-13 (2012) DOI: 10.1007/s00066-012-0237-6
131. O. J. Ott, S. Hertel, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome. Longterm results. Strahlenther Onkol, 190(3), 293-7 (2014) DOI: 10.1007/s00066-013-0504-1
132. O. J. Ott, C. Jeremias, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: Radiotherapy for calcaneodynia. Results of a single center prospective randomized dose optimization trial. Strahlenther Onkol, 189(4), 329-34 (2013) DOI: 10.1007/s00066-012-0256-3
133. O. J. Ott, C. Jeremias, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: Radiotherapy for achillodynia: results of a single-center prospective randomized dose-optimization trial. Strahlenther Onkol, 189(2), 142-6 (2013) DOI: 10.1007/s00066-012-0240-y
134. F. Rodel, D. Hofmann, J. Auer, L. Keilholz, M. Rollinghoff, R. Sauer and H. U. Beuscher: The anti-inflammatory effect of low-dose radiation therapy involves a diminished CCL20 chemokine expression and granulocyte/endothelial cell adhesion. Strahlenther Onkol, 184(1), 41-7 (2008) DOI: 10.1007/s00066-008-1776-8
135. P. Kern, L. Keilholz, C. Forster, M. H. Seegenschmiedt, R. Sauer and M. Herrmann: In vitro apoptosis in peripheral blood mononuclear cells induced by lowdose radiotherapy displays a discontinuous dose-dependence. Int J Radiat Biol, 75(8), 995-1003 (1999) DOI: 10.1080/095530099139755
136. B. Lodermann, R. Wunderlich, S. Frey, C. Schorn, S. Stangl, F. Rodel, L. Keilholz, R. Fietkau, U. S. Gaipl and B. Frey: Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-1beta by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol, 88(10), 727-34 (2012) DOI: 10.3109/09553002.2012.689464
137. R. Wunderlich, A. Ernst, F. Rodel, R. Fietkau, O. Ott, K. Lauber, B. Frey and U. S. Gaipl: Low and moderate dose of ionising radiation up to 2 Gy modulates transmigration and chemotaxis of activated macrophages, provokes an anti-inflammatory cytokine milieu, but does not impact on viability and phagocytic function. Clin Exp Immunol (2014) No DOI Found
138. M. Orth, K. Lauber, M. Niyazi, A. A. Friedl, M. Li, C. Maihofer, L. Schuttrumpf, A. Ernst, O. M. Niemoller and C. Belka: Current concepts in clinical radiation oncology. Radiat Environ Biophys, 53(1), 1-29 (2014) DOI: 10.1007/s00411-013-0497-2
139. U. S. Gaipl, G. Multhoff, H. Scheithauer, K. Lauber, S. Hehlgans, B. Frey and F. Rodel: Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy, 6(5), 597-610 (2014) DOI: 10.2217/imt.14.38
140. H. E. Barker, J. T. Paget, A. A. Khan and K. J. Harrington: The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer, 15(7), 409-25 (2015) DOI: 10.1038/nrc3958
141. K. R. Jones, L. W. Elmore, C. Jackson-Cook, G. Demasters, L. F. Povirk, S. E. Holt and D. A. Gewirtz: p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol, 81(6), 445-58 (2005) DOI: 10.1080/09553000500168549
142. R. S. Roberson, S. J. Kussick, E. Vallieres, S. Y. Chen and D. Y. Wu: Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res, 65(7), 2795-803 (2005) DOI: 10.1158/0008-5472.CAN-04-1270
143. S. Chakradeo, L. W. Elmore and D. A. Gewirtz: Is senescence reversible? Curr Drug Targets (2015) No DOI Found
144. M. Hollstein, D. Sidransky, B. Vogelstein and C. C. Harris: p53 mutations in human cancers. Science, 253(5015), 49-53 (1991) DOI: 10.1126/science.1905840
145. K. K. Tsai, J. Stuart, Y. Y. Chuang, J. B. Little and Z. M. Yuan: Low-dose radiation-induced senescent stromal fibroblasts render nearby breast cancer cells radioresistant. Radiat Res, 172(3), 306-13 (2009) DOI: 10.1667/RR1764.1
146. P. C. Wu, Q. Wang, L. Grobman, E. Chu and D. Y. Wu: Accelerated cellular senescence in solid tumor therapy. Exp Oncol, 34(3), 298-305 (2012) No DOI Found
147. R. Sidi, G. Pasello, I. Opitz, A. Soltermann, M. Tutic, H. Rehrauer, W. Weder, R. A. Stahel and E. Felley-Bosco: Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur J Cancer, 47(2), 326-32 (2011) DOI: 10.1016/j.ejca.2010.09.044
148. S. D. Tyner, S. Venkatachalam, J. Choi, S. Jones, N. Ghebranious, H. Igelmann, X. Lu, G. Soron, B. Cooper, C. Brayton, S. H. Park, T. Thompson, G. Karsenty, A. Bradley and L. A. Donehower: p53 mutant mice that display early ageing-associated phenotypes. Nature, 415(6867), 45-53 (2002) DOI: 10.1038/415045a
149. A. M. Haugstetter, C. Loddenkemper, D. Lenze, J. Grone, C. Standfuss, I. Petersen, B. Dorken and C. A. Schmitt: Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer, 103(4), 505-9 (2010) DOI: 10.1038/sj.bjc.6605784
150. L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi and E. A. Liu: In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science, 303(5659), 844-8 (2004) DOI: 10.1126/science.1092472
151. A. Ventura, D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder and T. Jacks: Restoration of p53 function leads to tumour regression in vivo. Nature, 445(7128), 661-5 (2007) DOI: 10.1038/nature05541
152. V. J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman and G. Selivanova: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med, 8(3), 282-8 (2002) DOI: 10.1038/nm0302-282
153. Y. Peng, C. Li, L. Chen, S. Sebti and J. Chen: Rescue of mutant p53 transcription function by ellipticine. Oncogene, 22(29), 4478-87 (2003) DOI: 10.1038/sj.onc.1206777
154. H. C. Chuang, L. P. Yang, A. L. Fitzgerald, A. Osman, S. H. Woo, J. N. Myers and H. D. Skinner: The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells. PLoS One, 9(8), e104821 (2014) DOI: 10.1371/journal.pone.0104821
155. K. M. Burchett, Y. Yan and M. M. Ouellette: Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One, 9(1), e85155 (2014) DOI: 10.1371/journal.pone.0085155
156. A. E. Hochreiter, H. Xiao, E. M. Goldblatt, S. M. Gryaznov, K. D. Miller, S. Badve, G. W. Sledge and B. S. Herbert: Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res, 12(10), 3184-92 (2006) DOI: 10.1158/1078-0432.CCR-05-2760
157. S. Chakraborty, M. Jain, A. R. Sasson and S. K. Batra: MUC4 as a diagnostic marker in cancer. Expert Opin Med Diagn, 2(8), 891-910 (2008) DOI: 10.1517/17530059.2.8.891
158. M. A. Macha, S. Rachagani, P. Pai, S. Gupta, W. M. Lydiatt, R. B. Smith, S. L. Johansson, S. M. Lele, S. S. Kakar, J. H. Lee, J. Meza, A. K. Ganti, M. Jain and S. K. Batra: MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene, 34(13), 1698-708 (2015) DOI: 10.1038/onc.2014.102
159. Y. Meng, E. V. Efimova, K. W. Hamzeh, T. E. Darga, H. J. Mauceri, Y. X. Fu, S. J. Kron and R. R. Weichselbaum: Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol Ther, 20(5), 1046-55 (2012) DOI: 10.1038/mt.2012.19
160. I. B. McInnes and G. Schett: The pathogenesis of rheumatoid arthritis. N Engl J Med, 365(23), 2205-19 (2011) DOI: 10.1056/NEJMra1004965
161. K. Taniguchi, H. Kohsaka, N. Inoue, Y. Terada, H. Ito, K. Hirokawa and N. Miyasaka: Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med, 5(7), 760-7 (1999) DOI: 10.1038/10480
162. J. P. Coppe, F. Rodier, C. K. Patil, A. Freund, P. Y. Desprez and J. Campisi: Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem, 286(42), 36396-403 (2011) DOI: 10.1074/jbc.M111.257071
163. V. Bours, G. Bonizzi, M. Bentires-Alj, F. Bureau, J. Piette, P. Lekeux and M. Merville: NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology, 153(1-3), 27-38 (2000) DOI: 10.1016/S0300-483X(00)00302-4
164. R. M. Laberge, L. Zhou, M. R. Sarantos, F. Rodier, A. Freund, P. L. de Keizer, S. Liu, M. Demaria, Y. S. Cong, P. Kapahi, P. Y. Desprez, R. E. Hughes and J. Campisi: Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell, 11(4), 569-78 (2012) DOI: 10.1111/j.1474-9726.2012.00818.x
165. H. D. Skinner, V. C. Sandulache, T. J. Ow, R. E. Meyn, J. S. Yordy, B. M. Beadle, A. L. Fitzgerald, U. Giri, K. K. Ang and J. N. Myers: TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res, 18(1), 290-300 (2012) DOI: 10.1158/1078-0432.CCR-11-2260
166. O. Moiseeva, X. Deschenes-Simard, E. St-Germain, S. Igelmann, G. Huot, A. E. Cadar, V. Bourdeau, M. N. Pollak and G. Ferbeyre: Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell, 12(3), 489-98 (2013) DOI: 10.1111/acel.12075
167. R. M. Memmott, J. R. Mercado, C. R. Maier, S. Kawabata, S. D. Fox and P. A. Dennis: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila), 3(9), 1066-76 (2010) DOI: 10.1158/1940-6207.CAPR-10-0055
168. M. Pollak: Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila), 3(9), 1060-5 (2010) DOI: 10.1158/1940-6207.CAPR-10-0175
169. K. Bhalla, B. J. Hwang, R. E. Dewi, W. Twaddel, O. G. Goloubeva, K. K. Wong, N. K. Saxena, S. Biswal and G. D. Girnun: Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila), 5(4), 544-52 (2012) DOI: 10.1158/1940-6207.CAPR-11-0228
170. M. N. Pollak: Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov, 2(9), 778-90 (2012) DOI: 10.1158/2159-8290.CD-12-0263
171. S. Uwe: Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol, 75(8), 1567-79 (2008) DOI: 10.1016/j.bcp.2007.10.027
172. Y. Yamamoto and R. B. Gaynor: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest, 107(2), 135-42 (2001) DOI: 10.1172/JCI11914
173. B. Sehnert, H. Burkhardt, J. T. Wessels, A. Schroder, M. J. May, D. Vestweber, J. Zwerina, K. Warnatz, F. Nimmerjahn, G. Schett, S. Dubel and R. E. Voll: NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immunemediated diseases. Proc Natl Acad Sci U S A, 110(41), 16556-61 (2013) DOI: 10.1073/pnas.1218219110
174. M. A. Brach, R. Hass, M. L. Sherman, H. Gunji, R. Weichselbaum and D. Kufe: Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest, 88(2), 691-5 (1991) DOI: 10.1172/JCI115354
175. N. Kozakai, E. Kikuchi, M. Hasegawa, E. Suzuki, H. Ide, A. Miyajima, Y. Horiguchi, J. Nakashima, K. Umezawa, N. Shigematsu and M. Oya: Enhancement of radiosensitivity by a unique novel NF-kappaB inhibitor, DHMEQ, in prostate cancer. Br J Cancer, 107(4), 652-7 (2012) DOI: 10.1038/bjc.2012.321
176. G. Matsumoto, J. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi and K. Umezawa: Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res, 11(3), 1287-93 (2005)
177. H. Takatsuna and K. Umezawa: Screening of bioactive metabolites for pancreatic regeneration chemotherapy. Biomed Pharmacother, 58(10), 610-3 (2004) DOI: 10.1016/j.biopha.2004.10.003
178. D. V. Starenki, H. Namba, V. A. Saenko, A. Ohtsuru, S. Maeda, K. Umezawa and S. Yamashita: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res, 10(20), 6821-9 (2004) DOI: 10.1158/1078-0432.CCR-04-0463
179. J. S. Tilstra, A. R. Robinson, J. Wang, S. Q. Gregg, C. L. Clauson, D. P. Reay, L. A. Nasto, C. M. St Croix, A. Usas, N. Vo, J. Huard, P. R. Clemens, D. B. Stolz, D. C. Guttridge, S. C. Watkins, G. A. Garinis, Y. Wang, L. J. Niedernhofer and P. D. Robbins: NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest, 122(7), 2601-12 (2012) DOI: 10.1172/JCI45785
180. J. H. Cho, M. Dimri and G. P. Dimri: MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem, 290(16), 10555-67 (2015) DOI: 10.1074/jbc.M114.624361
181. K. C. Chan, C. M. Ting, P. S. Chan, M. C. Lo, K. W. Lo, J. E. Curry, T. Smyth, A. W. Lee, W. T. Ng, G. S. Tsao, R. N. Wong, M. L. Lung and N. K. Mak: A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer, 12(1), 128 (2013) DOI: 10.1186/1476-4598-12-128
182. A. Ernst, H. Anders, H. Kapfhammer, M. Orth, R. Hennel, K. Seidl, N. Winssinger, C. Belka, S. Unkel and K. Lauber: HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Lett, 365(2), 211-22 (2015) DOI: 10.1016/j.canlet.2015.05.024